Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Haughney

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Trials|April 15, 2022
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)Seonaidh Cotton, Graham Devereux, Hassan Abbas, et al.
Plos One|April 13, 2023
The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysisDavid J Pascall, Elen Vink, Rachel Blacow, et al.
The Journal of Infection|June 3, 2023
Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistentDavid J Pascall, Elen Vink, Rachel Blacow, et al.
Nature Microbiology|July 7, 2022
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
Nature Microbiology|September 16, 2022
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Trials|April 15, 2022
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)Seonaidh Cotton, Graham Devereux, Hassan Abbas, et al.
Plos One|April 13, 2023
The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysisDavid J Pascall, Elen Vink, Rachel Blacow, et al.
The Journal of Infection|June 3, 2023
Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistentDavid J Pascall, Elen Vink, Rachel Blacow, et al.
Nature Microbiology|July 7, 2022
SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
Nature Microbiology|September 16, 2022
Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathwayBrian J Willett, Joe Grove, Oscar A MacLean, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
The Journal of Infection|April 21, 2023
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Annie Wright, et al.
Pageof 9